ERAS Erasca Inc
471
$2.63
$0.04
(1.54%)
| Watchers | 471 |
| 52-Wk Low | $1.51 |
| 52-Wk High | $3.38 |
| Market Cap | $717.51M |
| Volume | 2.93M |
| 52-Wk High | $3.38 |
| 52-Wk Low | $1.51 |
Erasca (NASDAQ:ERAS) PT Raised to $7.00Ticker Report • about 2 months ago
Erasca (NASDAQ:ERAS - Free Report) had its target price hoisted by The Goldman Sachs Group from $6.00 to $7.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The...
Share to Feed
Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Erasca (ERAS Research Report) and keeping the price target at $7.00...
HC Wainwright restated their buy rating on shares of Erasca (NASDAQ:ERAS - Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the...
Insights into Erasca Inc's Q4 and Full Year 2023 Financial and Operational PerformanceRelated Stocks: ERAS...
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript...
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript...
Funding from new and existing investors extends anticipated cash runway into H2 2026SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) ( Erasca ), a clinical-stage precision...
In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on Erasca (ERAS Research Report), with a price tar...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC Research Report) and Erasca (ERAS...
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...